Shire fuels hope for pharma M&A, but US deals will beat EU

M&A deals driven by pharmaceutical companies betting on the prospects of late pipeline assets, such as Shire’s recent deal, look set to be a recurrent theme in 2015. Other M&A drivers will be small to medium size transactions in Europe and aggressive activity from US companies, say Moody's credit analysts.